Authors
Latest:
Important Safety Data Evaluated in Meta-Analysis of MyelofibrosisJan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Latest:
Using Comprehensive Genomic Profiling to Identify Rare Subsets of Merkel Cell CarcinomaRyan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Latest:
EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung CancerIn this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.
Latest:
Integrating Physician Opinions Into DLBCL Treatment SelectionPatrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma
Latest:
T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup AnalysisFam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
Latest:
About the C-800 Trial of Botensilimab/Balstilimab in Ovarian CancerBruno Bockorny, MD, discusses the phase 1 C-800 trial of botensilimab plus bastilimab, specifically for patients in the C-800-01 cohort with recurrent platinum refractory/resistant ovarian cancer.
Latest:
Leukemia Awareness Month: Changing the Future of AML through Precision MedicineGwen Nichols, MD, reviews the evolving landscape of acute myeloid leukemia for Leukemia Awareness Month.
Latest:
Unmet Needs in R/R MM and Clinical Practice PearlsClosing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.
Latest:
Dysphagia-Optimized IMRT Shows Significance in Head and Neck CancerChristopher Nutting, MD, discusses the results of a randomized phase 3 trial using dysphagia-optimized intensity modulated radiotherapy versus standard IMRT in patients with head and neck cancer.
Latest:
Role of Ruxolitinib in GVHD TreatmentDrs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.
Latest:
Clinical Insights on the Future of GVHD TreatmentClosing out his discussion on chronic graft-vs-host disease, Yi-Bin Chen, MD, looks to the future of GVHD treatment.
Latest:
Tumor-Infiltrating Lymphocytes: Rationale for Use in the Treatment of Solid Tumors and Potential Benefits and DrawbacksIn the second interview of this series, Ben Creelan, MD, Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Latest:
The Future of Treating Small Cell Lung CancerKartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.
Latest:
Findings of the IMMUTACE Trial in Hepatocellular CarcinomaArndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Latest:
Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in MyelomaMehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.
Latest:
PFS Data Support Approval of Fam-Trastuzumab Deruxtecan-nxki for HER2+ Breast CancerYeon Hee Park, MD, discusses the data supporting the FDA’s accelerated approval of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.
Latest:
Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AMLMikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.
Latest:
Evaluating Ways of Measuring MRD in Hematologic MalignanciesJerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Latest:
Methods and Design of the MYLUNG Consortium for mNSCLCNicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Latest:
Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World DataIn the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.
Latest:
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Latest:
Survival Advantage Observed in HER2+Breast Cancer With Brain MetastasisNancy U. Lin, MD, discusses the results from a substudy of HER2CLIMB looking at tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer and brain metastases.
Latest:
African Ancestry Among Patients with Colorectal Cancer May Correlate With Fewer Actionable AlterationsAt the AACR 2023 Annual Meeting, a presentation revealed that people with colorectal cancer and African ancestry are less likely to be candidates for targeted therapy.
Latest:
Increased Rates of Viral Infections in Multiple MyelomaHeinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Latest:
Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid CarcinomaChristine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Latest:
Comparing Tandem Stem Cell Transplant Approaches in Multiple MyelomaNicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Improving Upon Immunotherapy Advances in HCCBruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.
